Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RESCUE: A Randomized, Blinded, Placebo-controlled, Parallel Group Design to Determine the Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy

Next Previous
X
Search
Trial Profile

RESCUE: A Randomized, Blinded, Placebo-controlled, Parallel Group Design to Determine the Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RNS 60 (Primary)
  • Indications Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RESCUE
  • Sponsors Revalesio

    • Most Recent Events

    • 18 Apr 2024 Results (n=82)investigating RNS60 in population of stroke patients, presented at the 76th Annual Meeting of the American Academy of Neurology 2024
    • 07 Feb 2024 according to a Revalesio media release, data from this trial will be presented in an oral presentation at the Late-Breaking Science session of the International Stroke Conference (ISC) 2024. The conference is being held February 7-9, 2024, in Phoenix, AZ.
    • 07 Feb 2024 Results published in the Revalesio Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top